Development of a highly sensitive point-of-care test to detect SARS-CoV-2 from saliva combining a simple RNA extraction method with colorimetric reverse transcription loop-mediated isothermal amplification detection

Wataru Yamazaki^{1, 3, 4}, Yasufumi Matsumura², Uraivan Thongchankaew-Seo¹,
Yasuko Yamazaki¹, Miki Nagao²

¹Center for Southeast Asian Studies, Kyoto University, 46 Shimoadachi-cho, Yoshida, Sakyo-ku, Kyoto 606-8501, Japan.

²Department of Clinical Laboratory Medicine, Kyoto University Graduate School of Medicine, 54 Shogoin-kawahara-cho, Sakyo-ku, Kyoto 606-8507, Japan.

³Kyoto University Graduate School of Medicine, Konoe-cho, Yoshida, Sakyo-ku, Kyoto 606-8303, Japan.

⁴Kyoto University School of Public Health, Konoe-cho, Yoshida, Sakyo-ku, Kyoto 606-8303, Japan.

Running headline: Sensitive POCT for COVID-19 from saliva

Abstract

To diagnose COVID-19 patients in the field, a sensitive point-of-care test using saliva was developed. Using a heat block without centrifuge, the test took 45 minutes. Naked eye judgement with color change dye outperformed the reference standard, with a diagnostic sensitivity of 82.6% (19/23) and diagnostic specificity of 100% (21/21).

Keywords: COVID-19; LAMP; Point-of-care test; POCT; SARS-CoV-2, Semi Alkaline Proteinase

Introduction

With progressing globalization, the worldwide spread of infectious diseases has accelerated. The new coronavirus infection (COVID-19) is a major public health concern (WHO, 2020). With the high burden and risk for infection among patients and healthcare workers, the advent of reverse transcription quantitative real-time polymerase chain reaction (RT-qPCR) testing as an alternative to nasopharyngeal swab sampling for diagnosing COVID-19 has increased the use of saliva (Azzi et al., 2020; Iwasaki et al., 2020; Nagura-Ikeda et al., 2020; To et al., 2020; Vogels et al., 2020; Williams et al., 2020; Wyllie et al., 2020).

Angiotensin-converting enzyme II (ACE2), the main receptor for SARS-CoV-2 entry into human cells, is highly expressed on the oral cavity mucosa, especially tongue epithelial cells (Iwasaki et al., 2020; Xu et al., 2020). In Japan, many COVID-19 cases have been found in metropolitan entertainment districts, where food, drink, and conversation are frequent. Saliva droplets containing SARS-COV-2 are a major vector for COVID-19 infection, making saliva a promising candidate for COVID-19 testing (Azzi et al., 2020; Nagura-Ikeda et al., 2020; Wyllie et al., 2020). While the viral load of SARS-CoV-2 in saliva samples is lower than in nasopharyngeal swab samples (Iwasaki et al., 2020; Williams et al., 2020), several researchers have reported comparable or better diagnostic sensitivity with saliva testing (Azzi et al., 2020; Nagura-Ikeda et al., 2020; To et al., 2020; Vogels et al., 2020; Wyllie et al., 2020).

The combined use of the direct-to-test addition by heating and RT-qPCR using a nasopharyngeal swab sample has proven successful due to reduced inhibitory

effects (Esbin et al., 2020). However, the saliva sample must undergo high-speed centrifugation at 20,000 *g* for 5-30 min following purification with a commercial RNA extraction kit to remove potential inhibitors (Azzi et al., 2020; Iwasaki et al., 2020; Nagura-Ikeda et al., 2020; To et al., 2020; Williams et al., 2020; Wyllie et al., 2020). This tedious RNA extraction process, which requires a well-equipped laboratory, is a major hurdle for performing sensitive point-of-care testing (POCT) for COVID-19 using saliva.

Reverse transcription loop-mediated isothermal amplification (RT-LAMP) is an attractive option for achieving more-sensitive POCT than an immunochromatographic assay because of its broader utility and portable real-time detector with an in-house battery or combination use with a cost-effective heat block and colorimetric reagent (Augustine et al., 2020; Ecker et al., 2020; Hayashida et al., 2015; Park, et al., 2020).

Here, we developed a simple method for extracting RNA from saliva samples using semi-alkaline proteinase (SAP), a sputum homogenizer for tuberculosis examinations, and a subsequent simple heating step, with no need for centrifugation or RNA extraction. Further, we newly developed a triplex RT-LAMP approach using colorimetric readout in a heat block for the naked eye judgement. We preliminarily evaluated the POCT performance with 44 clinical saliva samples.

The study

We used Primer Explorer V5 (primerexplorer.jp/lampv5e/index.html) to design three primer sets targeting the ORF 1ab, S, and ORF 7a regions to simultaneously detect SARS-CoV-2 with high sensitivity and robustness. To identify highly conserved nucleotide sequences with low similarity to SARS-CoV-1 sequences, we performed multiple sequence alignment using Clustal Omega (www.ebi.ac.uk/Tools/msa/clustalo) of 490 whole-genome SARS-Cov-2 sequences from the DDBJ/EMBL/GenBank databases (www.ncbi.nlm.nih.gov/nucleotide/) submitted by worldwide researchers from five continents. The details of each primer and in-house reagent are shown in S-Tables 1-3. Artificially synthesized SARS-CoV-2 sequences (Eurofins, Tokyo, Japan) corresponding to the three target regions and RNA extracted from healthy human saliva were used as positive and negative controls, respectively, for the triplex RT-LAMP format.

From May to July 2020, we collected at least 1 ml of saliva samples from 44 clinical patients suspected of having COVID-19 infection at Kyoto University Hospital or Kyoto City Hospital. The saliva samples were mixed with 3 strength-volume of SAP (Semi-Alkaline Proteinase, Suputazyme; Kyokuto Pharmaceutical Industrial, Tokyo, Japan) manually or using a vortex mixer for 15 sec. After incubation for 15 min at room temperature to dissolve the saliva components, each of the saliva-SAP mixtures (SS mixes) were added to a 1.5-ml microcentrifuge tube. For RNA extraction, 140 µl of each SS mix was eluted into 60 µl using a QIAamp Viral RNA Mini Kit (Qiagen, Hilden, Germany). RT-qPCR using the N2 primers and probe was performed with 5 µl of the extracted RNA in 20 µl of reaction mixture in LightCycler 480 System II (Roche,

Basel, Switzerland) according to the protocol recommended by the National Institute of Infectious Diseases, Japan (Shirato et al., 2020). Ten-fold serial dilutions (5 to 5×10^6 copies/reaction) of the synthesized RNA containing the target sequence (Shirato et al., 2020) were used to calculate the viral loads in clinical samples.

In parallel, for POCT, the remaining SS mix was heated at 95 °C for 5 min, and then the tube was centrifuged using a dry-cell battery-powered tabletop centrifuge for approximately 5 sec or swung manually to remove the aqueous droplet on the tube lid. Using 50 µl of RT-LAMP reaction mixtures (including 10 µl of template), the RT-LAMP reaction was monitored using a LightCycler 480 System II (Roche) at 63 °C for 25 min. Subsequent procedures were completed without interruption, or else the SS mix was stored at -80 °C until used. The limit of detection (LOD) of triplex RT-LAMP was defined as the lowest concentration at which 95% of positive samples were detected using a 2-fold series of phosphate-buffered saline dilutions in maximum 20 replicates of 50,000, 25,000, 12,500, and 10,000 copies/ml of heat-inactivated SARS-CoV-2 (ATCC VR-1986HK; American Type Culture Collection, Manassas, VA, USA) (Table 2). The dilutions were heated at 95 °C for 5 min. After removal of the aqueous droplet on the tube lid, 10 µl of the template was applied to 50 µl of RT-LAMP reaction mixture, as described above.

Compared to reference standard, the diagnostic sensitivity and specificity were 82.6% (19/23; 95% confidence interval [CI], 61.2%-95.1%) and 100% (21/21, 95% CI, 83.8%-100%) for the new POCT, which took 45 min from starting crude RNA extraction to endpoint readout with the naked eye (Table 1, Figure 1). As shown in Table 1, 18 clinical samples exceeding 380 copies/reaction (>33,000 copies/ml of

saliva) by reference standard measurement were positive on POCT between 9:02 and 16:12 for amplification. Three samples showing low copy numbers at 170-230 copies/reaction (15,000-20,000 copies/ml of saliva) on RT-qPCR were only 1 positive at 23:32 and 2 false negatives in POCT, which were interpreted as borderline samples near the LOD of POCT. Another 2 samples showing lower copy numbers at 13-86 copies/reaction (1,100-7,400 copies/ml of saliva) were both false negatives, possibly due to below the detection power of the POCT. The result obtained by the LOD determination was the value of 250 copies/reaction (25,000 copies/ml) (Table 2).

Conclusion

Our newly developed POCT approach achieved simple RNA extraction and constant RT-LAMP without the need for high-speed centrifugation, nucleic acid extraction kits, or qPCR equipment. This POCT does not require expensive equipment and performs comparably to an existing reference standard. This POCT can thus be used for drive-through testing and simple inspection stations in a field setting, helping reduce the risk of infection by simplifying and accelerating testing for COVID-19.

Acknowledgements

This research was supported by AMED under Grant Number JP20he0622031.

Conflict of Interest Statement

The authors declare that they have no conflicts of interest. All authors contributed to the study conception and design. WY, UTS, and YY developed RT-LAMP. YM and MN conducted POCT with clinical samples. WY and MN organized the study. WY and YM wrote the manuscript, and all authors read and approved the final manuscript.

Ethics approval

The Ethics Committee of Kyoto University Graduate School and the Faculty of Medicine approved this study (R2379) and waived the need for obtaining informed consent from each patient.

First author biographical sketch

Wataru Yamazaki is a veterinarian and microbiologist. He specializes in food microbiology and infectious diseases for both humans and animals and has been particularly involved in the development of LAMP and other molecular-based testing methods as well as POCT for fieldwork for over 15 years.

References

1. Azzi Lorenzo, Giulio Carcano, Francesco Gianfagna, Paolo Grossi, Daniela Dalla Gasperina, Angelo Genoni, Mauro Fasano, Fausto Sessa, Lucia Tettamanti, Francesco Carinci, Vittorio Maurino, Agostino Rossi, Angelo Tagliabue, Andreina Baj. (2020). Saliva is a reliable tool to detect SARS-CoV-2, *Journal of Infection*, 81 (1), e45-e50, doi.org/10.1016/j.jinf.2020.04.005.
2. Augustine R, Hasan A, Das S, Ahmed R, Mori Y, Notomi T, et al. (2020). Loop-Mediated Isothermal Amplification (LAMP): A Rapid, Sensitive, Specific, and Cost-Effective Point-of-Care Test for Coronaviruses in the Context of COVID-19 Pandemic. *Biology (Basel)*. 9(8).
3. Eckel F, Küsters F, Drossel B, Konert M, Mattes H, Schopf S. (2020). Variplex™ test system fails to reliably detect SARS-CoV-2 directly from respiratory samples without RNA extraction [published online ahead of print, 2020 Jul 17]. *Eur J Clin Microbiol Infect Dis*. 2020;1-5. doi:10.1007/s10096-020-03983-9
4. Esbin MN, Whitney ON, Chong S, Maurer A, Darzacq X, Tjian R. (2020). Overcoming the bottleneck to widespread testing: a rapid review of nucleic acid testing approaches for COVID-19 detection. *RNA*. 26(7), 771-783. doi:10.1261/rna.076232.120
5. Hayashida, K., Kajino, K., Hachaambwa, L., Namangala, B. and Sugimoto, C. (2015) Direct blood dry LAMP: a rapid, stable, and easy diagnostic tool for Human African Trypanosomiasis. *PLoS Negl Trop Dis* 9: e0003578. doi: 10.1371/journal.pntd.0003578.
6. Iwasaki, S., Fujisawa, S., Nakakubo, S., Kamada, K., Yamashita, Y., Fukumoto,

- T., Sato, K., Oguri, S., Taki, K., Senjo, H., Sugita, J., Hayasaka, K., Konno, S., Nishida, M., & Teshima, T. (2020). Comparison of SARS-CoV-2 detection in nasopharyngeal swab and saliva. *The Journal of infection*, 81(2), e145–e147. <https://doi.org/10.1016/j.jinf.2020.05.071>.
7. Nagura-Ikeda M, Imai K, Tabata S, Miyoshi K, Murahara N, Mizuno T, et al. (2020). Clinical evaluation of self-collected saliva by RT-qPCR, direct RT-qPCR, RT-LAMP, and a rapid antigen test to diagnose COVID-19. *J Clin Microbiol. JCM.01438-20*; DOI: 10.1128/JCM.01438-20.
8. Park Gun-Soo, Keunbon Ku, Seung-Hwa Baek, Seong-Jun Kim, Seung Il Kim, Bum-Tae Kim, Jin-Soo Maeng. (2020). Development of Reverse Transcription Loop-Mediated Isothermal Amplification Assays Targeting Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), *The Journal of Molecular Diagnostics*, 22 (6), 729-735. doi.org/10.1016/j.jmoldx.2020.03.006.
9. Shirato K, Nao N, Katano H, Takayama I, Saito S, Kato F, Katoh H, Sakata M, Nakatsu Y, Mori Y, Kageyama T, Matsuyama S, Takeda M. (2020). Development of Genetic Diagnostic Methods for Novel Coronavirus 2019 (nCoV-2019) in Japan. *Jpn J Infect Dis.* 73 (4), 304-307. doi: 10.7883/yoken.JJID.2020.061.
10. To, K. K., Tsang, O. T., Yip, C. C., Chan, K. H., Wu, T. C., Chan, J. M., Leung, W. S., Chik, T. S., Choi, C. Y., Kandamby, D. H., Lung, D. C., Tam, A. R., Poon, R. W., Fung, A. Y., Hung, I. F., Cheng, V. C., Chan, J. F., & Yuen, K. Y. (2020). Consistent Detection of 2019 Novel Coronavirus in Saliva. *Clinical infectious diseases: an official publication of the Infectious Diseases Society of America*, 71(15), 841–843. doi.org/10.1093/cid/ciaa149.

11. Vogels CB, Watkins AE, Harden CA, et al. SalivaDirect: A simplified and flexible platform to enhance SARS-CoV-2 testing capacity. medRxiv; 2020. DOI: 10.1101/2020.08.03.20167791.
12. World Health Organization (WHO). (2020) Coronavirus disease 2019 (COVID-2019) situation reports. <https://www.who.int/emergencies/diseases/novel-coronavirus-2019/situation-reports> (accessed 25 October 2020).
13. Williams, E., K. Bond, B. Zhang, M. Putland and D. A. Williamson (2020). "Saliva as a non-invasive specimen for detection of SARS-CoV-2." Journal of Clinical Microbiology: JCM.00776-00720.
14. Wyllie AL, Fournier J, Casanovas-Massana A, et al. "Saliva or Nasopharyngeal Swab Specimens for Detection of SARS-CoV-2" [published online ahead of print, 2020 Aug 28]. N Engl J Med. 2020;10.1056/NEJMc2016359. doi:10.1056/NEJMc2016359.
15. Xu H, Zhong L, Deng J, Peng J, Dan H, Zeng X, et al. High expression of ACE2 receptor of 2019-nCoV on the epithelial cells of oral mucosa. Int J Oral Sci. 2020 Feb 24;12(1):8. PubMed PMID: 32094336. Pubmed Central PMCID: PMC7039956.

Table 1. Results of POCT and reference standard in 44 clinical patients.

Sample ID	Time of positivity	Copies/reaction tube by reference standard	Copies/ml of saliva
<i>N</i> = 23		RT-qPCR positive	
AR+26	Negative	13	1,100
AR+23	Negative	86	7,400
AR+24	23:32	170	15,000
AR+03	Negative	180	15,000
AR+11	Negative	230	20,000
AR+22	12:05	380	33,000
AR+20	14:35	590	51,000
AR+04	14:34	1,300	110,000
AR+16	13:37	2,500	210,000
AR+21	12:11	3,800	330,000
AR+17	16:12	8,000	690,000
AR+06	13:11	9,300	800,000
AR+25	12:11	16,000	1,400,000
AR+18	14:43	24,000	2,100,000
AR+07	12:56	34,000	2,900,000
AR+08	11:59	45,000	3,900,000
AR+14	11:36	120,000	10,000,000

AR+09	10:58	130,000	11,000,000
AR+10	10:17	190,000	16,000,000
AR+15	09:49	530,000	45,000,000
AR+27	09:02	1,600,000	140,000,000
AR+13	09:06	1,700,000	150,000,000
AR+12	13:51	3,600,000	310,000,000

$N = 21$

Negative RT-qPCR negative

POCT, Point-of-care test.

RT-qPCR, Reverse transcription quantitative real-time polymerase chain reaction

Table 2. LOD determination of the triplex RT-LAMP with the heat-inactivated SARS-CoV-2, ATCC VR-1986HK in phosphate-buffered saline.

Copies/ml	50,000	25,000	12,500	10,000
Copies/reaction	500	250	125	100
Positive/tested (%)	8/8 (100%)	20/20 (100%)	6/10 (60%)	3/6 (50%)

ATCC, American Type Culture Collection.

LOD, Limit of detection.

RT-LAMP, Reverse transcription loop-mediated isothermal amplification detection.

SARS-CoV-2, Severe acute respiratory syndrome coronavirus 2.

Figure legend

Figure 1. Concept of POCT using a combination of simple RNA extraction and LAMP devices

Technical Appendix. S-Table 1. Primers used for RT-LAMP assay.

Primer	Sequences (5'-3')	Location*	Target
F3-1ab	TGCTAGATTTTACTTTTACACCAG	4522 - 4545	ORF1ab
B3-1ab	CAGGTGTTTTAGAAGAAGAAGT	4757 - 4736	
FIP-1ab	CCAAGTGGCATTGTAACAAGAGTTT-TAAAACAACGTAGCGTCAC	4617 - 4593, 4546 - 4565	
BIP-1ab	TGCTCGGTATATGAGATCTCTCAA-CGCTGTAACAGCATCAGG	4651 - 4674, 4720 - 4674	
FLP-1ab	CATTTAGATCGTTAAGTGTGTTGA	4592 - 4569	
BLP-1ab	AGTGCCAGCTACAGTTTCT	4675 - 4693	
F3-S	TCTTTCACACGTGGTGTT	21653 - 21670	Spike glycoprotein
B3-S	GTACCAAAAATCCAGCCTC	21885 - 21867	
FIP-S	CATGGAACCAAGTAACATTGGAAAA-CCTGACAAAGTTTTTCAGATCC	21761 - 21737, 21677 - 21697	

BIP-S	CTCTGGGACCAATGGTACTAAGAG-GACTTCTCAGTGGAAGCA	21772 - 21795, 21855 - 21838	ORF7ab
FLP-S	GGTAAGAACAAGTCCTGAGTTGAAT	21732 - 21708	
BLP-S	GTTTGATAACCCTGTCCTACCATT	21796 - 21819	
F3-7ab	GCACTGACTTGCTTTAGC	27556 - 27573	
B3-7ab	TGAAAGTTCAATCATTCTGTCTT	27770 - 27748	
FIP-7ab	AGGTGAAACTGATCTGGCACG-AATTTGCTTTTGCTTGTCTG	27645 - 27625, 27578 - 27598	
BIP-7ab	AGACAAGAGGAAGTTCAAGAACTTT-TGAGTGTGAAGCAAAGTGT	27658 - 27682, 27742 - 27724	
FLP-7ab	GATAGACGTGTTTTACGCCGT	27619 - 27599	
BLP-7ab	CTCCAATTTTCTTATTGTTGCGGC	27686 - 27710	

*: Corresponding to the GenBank accession No. NC_045512.2.

S-Table 2. Composition of the RT-LAMP reaction mixture including the homemade master mix.

RT-LAMP reaction mix	Triplex			
4x LAMP Master Mix	12.5	μl		
Distilled water	11.5	μl		
1x Primer mix for 1ab	2.6	μl		
1x Primer mix for S	2.6	μl		
1x Primer mix for 7a	2.6	μl		
CFI	2	μl		
<i>Bst</i> polymerase DNA Large Fragment (8 units/μl)	6	μl		
AMV Reverse Transcriptase for Genie III (20 units/μl)	0.2	μl		
<i>RNA template</i>	10	μl		
Total	50	μl		

Homemade 4x LAMP master mix	For 500		For 1000	
5 M Betaine	4	ml	8	ml
1 M Tris-HCl (pH8.8)	0.5	ml	1	ml
3 M Potassium chloride (KCl)	0.08	mL	0.16	mL
5.6 M (NH ₄) ₂ SO ₄	0.04	mL	0.08	mL
1 M MgSO ₄	0.2	mL	0.4	mL
100 mM dATP	0.35	mL	0.7	mL
100 mM dCTP	0.35	mL	0.7	mL
100 mM dGTP	0.35	mL	0.7	mL

100 mM dTTP	0.35	mL	0.7	mL
Tween20	0.05	ml	0.1	ml
Total (for 500/1000 samples)	6.27	ml	12.54	ml

CFI (Colori Fluorescent Indicator)	For 500	
Distilled water	0.6965	ml
10 mM HNB (Hydroxynaphthol blue)*	0.3	ml
Gel green (×10,000)	0.035	ml
Total (for 500 samples)	1.0	ml

* Distilled water :HNB powder = 1 ml:6 mg

Primer mix	For 500	
FIP (Inner F) (100 µm)	0.4	ml
BIP (Inner B) (100 µm)	0.4	ml
LF (Loop F) (100 µm)	0.2	ml
LB (Loop B) (100 µm)	0.2	ml
F3 (Outer F) (100 µm)	0.05	ml
B3 (Outer B) (100 µm)	0.05	ml
Total (for 500 samples)	1.3	ml

S-Table 3. Manufacturers' list for RT-LAMP reaction mix.

LAMP reagents	Manufacturers		
<i>4x LAMP Master Mix</i>			
Tris-HCl	Wako Industries	Pure Chemical	Osaka, Japan
Potassium chloride (KCl)	Sigma–Aldrich		St. Louis, MO, USA
(NH ₄) ₂ SO ₄	Sigma–Aldrich		St. Louis, MO, USA
Tween20	Sigma-Aldrich		St. Louis, MO, USA
MgSO ₄	New England Biolabs		Ipswich, MA, USA
Illustra dNTP set 100 mM, solutions 4 × 25 μmol	GE Healthcare		Little Chalfont, UK
5M Betain Solution 5 mL	Sigma–Aldrich		St. Louis, MO, USA
<i>CFI (Colori Fluorescent Indicator)</i>			

HNB (Hydroxynaphthol Blue)

MP Biomedicals

Aurora, OH, USA

Gel green (x10,000)

Biotium

Hayward, CA, USA

Bst polymerase DNA Large, Fragment (8 units/ μ L)

New England Biolabs

Ipswich, MA, USA

AMV Reverse Transcriptase, for Genie III (20 units/ μ L)

Nippon Gene

Tokyo, Japan

Primer (Recommended cartridge grade purification)

Hokkaido System Science

Sapporo, Japan

Fig. 1. Concept of POCT using a combination of simple RNA extraction and LAMP devices.